In the above video Dr. Follows discusses clinical trials, they are not for everyone. Suitability is an “individual thing” and requires consideration of many factors and discussion between the CLL patient and Doctor.
Q1) Do you think joining clinical trials is a way for CLL patients to get around access problems in the NHS?
Q2) Can you expect to have to travel to join a CLL clinical trial?
March 2015 treatment update written for CLLSA by Dr Christopher Fox, Nottingham University Hospitals NHS Trust,
Over a relatively short time period a remarkable number of effective new therapies have been developed for patients with CLL. In some instances, these treatments have gained a marketing authorisation licence in Europe and, currently, some are funded within the NHS for patients who meet specific criteria. However, patients and clinicians should be mindful that this is a rapidly developing field that is likely to further evolve over the next year or two.
Understanding Your Blood Results
Information videos by Dr Susan Leclair, Chancellor Professor in the Department of Medical Laboratory Science at the University of Massachusetts:
The videos will start as soon as the page opens:
In the above video Dr George Follows discusses testing, diagnosis and genetic profiling in CLL.
Much discussion is required between the patient and doctor when understanding where you are, as tests may be better at predicting for populations and there is much individual variation to consider.
For many, it's hard to understand why you would wait to treat cancer. In the above video, CLL experts, Dr. Michael Keating and Dr. Januario Castro, explain why it's necessary and beneficial to watch and wait with CLL. Dr. Castro shares the reasoning behind waiting to treat the condition, including lack of symptoms as well as side effects and toxicities. Dr. Keating explains how CLL is different from other cancers in that it's important to study the behaviour (watch) of this particular disease in order to decide the best treatment approach and when to begin treatment.
Diagnosis of CLL
Dr Samir Agrawal MB ChB, BSc, FRCP, FRCPath, PhD Consultant Haematologist, St. Bartholomew’s Hospital, Barts Health NHS Trust, London; Blizard Institute, Queen Mary University of London
Timothy Farren BSc(HONS) MIBMS, Clinical Scientist, St Bartholomew’s Hospital, Barts and The London School of Medicine, London.
The following article has been written in September 2012, exclusively for the CLL Support Association, It is aimed at patients and their carers and assumes almost no prior medical knowledge.